Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.38 |
| ▸ | LTA4H | P09960 | 2/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | WDR5 | P61964 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7795478 | 0.90 | MAPT (0.39) | L3MBTL1TDP1LTA4HPTPN1MAPT | |
| SCHEMBL7799028 | 0.85 | MAPT (0.37) | L3MBTL1LTA4HPTPN1MAPTWDR5 | |
| SCHEMBL7795186 | 0.81 | MEN1 (0.38) | HPGDALDH1A1GAA | |
| SCHEMBL7795476 | 0.80 | AR (0.35) | WDR5F2ALDH1A1 | |
| SCHEMBL7799040 | 0.77 | MEN1 (0.43) | L3MBTL1PTPN1MAPTHPGDALDH1A1 | |
| SCHEMBL29213722 | 0.68 | TDP1 (0.64) | TDP1MAPTHPGDALDH1A1 | |
| SCHEMBL7795236 | 0.67 | MEN1 (0.40) | L3MBTL1TDP1MAPTHPGDALDH1A1 | |
| SCHEMBL201784 | 0.67 | MEN1 (0.59) | TDP1MAPTALDH1A1GAA | |
| SCHEMBL13244238 | 0.67 | TSHR (0.48) | TDP1MAPTWDR5ALDH1A1GAA | |
| SCHEMBL13017224 | 0.66 | F2 (0.47) | F2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010012901-A1 | Sulphonyl compounds for use as linkers in solid phase and combinatorial synthesis | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2001-08-09 | — | — | US | disclosed |
| US-6225480-B1 | FOR SYNTHESIS OF ORGANIC COMPOUNDS CONTAINING--NH--GROUPS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-01 | — | — | US | disclosed |
| EP-0948480-A1 | SULPHONYL COMPOUNDS FOR USE AS LINKERS IN SOLID PHASE AND COMBINATORIAL SYNTHESIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998029386-A1 | SULPHONYL COMPOUNDS FOR USE AS LINKERS IN SOLID PHASE AND COMBINATORIAL SYNTHESIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010012901-A1 | Sulphonyl compounds for use as linkers in solid phase and combinatorial synthesis | H1-0, H1-2, ASH2L | L3MBTL1 567/4885TDP1 2593/4885TBXAS1 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.